{"gene":"PLD2","run_date":"2026-04-28T19:45:44","timeline":{"discoveries":[{"year":2014,"finding":"ARF6 and its effector PLD2 regulate syntenin exosome biogenesis by controlling the budding of intraluminal vesicles (ILVs) into multivesicular bodies (MVBs), identifying a novel pathway for ILV budding and exosome production.","method":"siRNA knockdown, dominant-negative mutants, electron microscopy, functional rescue experiments","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (siRNA, dominant-negatives, EM), replicated mechanistic epistasis in a high-citation paper","pmids":["24637612"],"is_preprint":false},{"year":2016,"finding":"Elevated membrane tension acts through PLD2 and mTORC2 to limit actin nucleation in neutrophils; loss of this pathway causes larger leading edges, higher membrane tension, and defective chemotaxis.","method":"Genetic knockdown/knockout, optogenetic membrane tension manipulation, mathematical modeling, live-cell imaging","journal":"PLoS Biology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods with clean loss-of-function phenotype and pathway placement, high citation count","pmids":["27280401"],"is_preprint":false},{"year":2000,"finding":"PLD2 physically interacts with Type Iα PIPkinase; PLD2 recruits PIPkinase to its intracellular location and its activity in vivo is regulated solely by local PtdIns(4,5)P2 levels generated by this kinase.","method":"Co-immunoprecipitation, overexpression in COS7 cells, in vivo activity assays","journal":"The EMBO Journal","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP plus functional activity rescue, high citation count","pmids":["11032811"],"is_preprint":false},{"year":1998,"finding":"PLD2 (but not PLD1) constitutively associates with the EGF receptor in a ligand-independent manner and is tyrosine-phosphorylated at Tyr-11 upon EGF receptor activation; mutation Y11F enhances basal PLD2 activity ~2-fold.","method":"Co-immunoprecipitation, site-directed mutagenesis, transient transfection in HEK293 cells, lipase activity assay","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1/2 — mutagenesis plus co-IP plus activity assay, high citation count","pmids":["9837959"],"is_preprint":false},{"year":2004,"finding":"Alpha-synuclein inhibits PLD2 in vitro; inhibition requires an alpha-helical conformation stabilized by exon 4 residues and residues in exon 6 (C-terminal 130–140); phosphorylation at S129, Y125, or Y136 abolishes PLD2 inhibition by alpha-synuclein.","method":"In vitro PLD2 activity assay with recombinant proteins, deletion and point mutants of alpha-synuclein, phosphomimetic mutations","journal":"Journal of Molecular Biology","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro with systematic mutagenesis","pmids":["15033366"],"is_preprint":false},{"year":2006,"finding":"PLD2 forms a functional complex with mTOR/raptor via a TOS-like motif (Phe-Glu-Val-Gln-Val, aa 265–269) in PLD2; PLD2-dependent mTOR activation requires both binding to raptor and lipase activity, as lipase-inactive PLD2 cannot activate mTOR despite binding raptor.","method":"siRNA knockdown, co-immunoprecipitation, site-directed mutagenesis, S6K1/4EBP1 phosphorylation assays","journal":"Cellular Signalling","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP, mutagenesis, and functional rescue with defined mechanistic pathway","pmids":["16837165"],"is_preprint":false},{"year":2006,"finding":"PLD2 is required for leukocyte chemotaxis; PLD2 enzymatic activity mediates ENA-78/CXCR-2-induced chemotaxis, and both PLD2 isoforms associate with cell polarity and F-actin polymerization in response to IL-8.","method":"siRNA knockdown, overexpression of lipase-inactive mutant, in vitro chemotaxis assay, immunofluorescence microscopy","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — lipase-dead mutant plus siRNA with defined phenotypic readout","pmids":["16873675"],"is_preprint":false},{"year":2000,"finding":"PLD2 can be activated by calcium-mobilizing agonists and by co-expression with PKCα (but not PKCδ) in Sf9 cells; PLD1 and PLD2 physically associate with PKC isoforms and can be stimulated by calmodulin and PKCα-enriched cytosol in reconstitution assays.","method":"Co-expression in Sf9 cells, immunoprecipitation, membrane reconstitution assays, PtdEth production assay","journal":"Biochimica et Biophysica Acta","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP and functional assay from single lab","pmids":["10838164"],"is_preprint":false},{"year":2004,"finding":"VEGFR-2 and PLD2 co-localize in endothelial caveolae; VEGF activates PLD via VEGFR-2/PKC-δ, and PLD-generated phosphatidic acid is required for VEGF-induced MEK/ERK phosphorylation and endothelial cell proliferation.","method":"Subcellular fractionation, 1-butanol inhibition, phosphatidic acid rescue, pharmacological inhibitors, caveolae disruption with MβCD","journal":"American Journal of Physiology Heart and Circulatory Physiology","confidence":"Medium","confidence_rationale":"Tier 2/3 — fractionation plus pharmacological inhibition with functional rescue","pmids":["14704231"],"is_preprint":false},{"year":2011,"finding":"PLD2 directly binds to Rac2 and functions as a guanine nucleotide exchange factor (GEF), promoting GDP dissociation (~72% decrease) and GTP association (~300% increase) on Rac2; GEF activity is independent of lipase activity. The PLD2-Rac2 interaction involves CRIB-region residues 263–266 in the PH domain and the PX domain of PLD2, and Switch-1 residue N17 of Rac2.","method":"In vitro GEF assay with recombinant proteins, co-immunoprecipitation, site-directed mutagenesis, FRET in living cells, cell functional assays (adhesion, chemotaxis, phagocytosis)","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro GEF assay plus mutagenesis plus FRET in living cells","pmids":["22106281"],"is_preprint":false},{"year":2011,"finding":"PLD2 co-localizes with Grb2 and actin-rich membrane protrusions in macrophages; PLD2 interacts with Grb2 via Y169 (SH2 domain), which enhances PLD activity and, together with Rac2, drives actin polymerization and membrane ruffle formation.","method":"YFP/CFP fluorescent chimeras, immunoprecipitation, site-directed mutagenesis (Y169F, Grb2-R86K), overexpression, actin polymerization assay","journal":"Cellular Signalling","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP, mutagenesis, and live-cell imaging with functional phenotype","pmids":["21419846"],"is_preprint":false},{"year":2006,"finding":"PLD2 residues Y169 and Y179 form two SH2 binding sites for Grb2: Y169 modulates enzymatic activity and Y179 regulates tyrosine phosphorylation of PLD2; Y169 also mediates cellular proliferation through Ras/MAPK when Y179 regulation is released.","method":"GST pull-down, co-immunoprecipitation, deletion and point mutants, DNA synthesis assay, ERK phosphorylation","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — multiple mutagenesis studies with orthogonal functional readouts","pmids":["16407827"],"is_preprint":false},{"year":2007,"finding":"Grb2 is essential for PLD2 activity in vivo; Grb2 interacts with PLD2 via its SH2 domain (PLD2-Y169), and after EGF stimulation, Grb2 re-localizes PLD2 to Golgi-like perinuclear structures via its SH2 domain.","method":"shRNA stable knockdown, rescue with shRNA-resistant Grb2, co-immunoprecipitation, immunofluorescence microscopy, primary HUVEC imaging","journal":"Journal of Molecular Biology","confidence":"High","confidence_rationale":"Tier 2 — shRNA knockdown plus rescue plus localization imaging with functional consequence","pmids":["17276458"],"is_preprint":false},{"year":2005,"finding":"PLD2 exists in a ternary complex with protein tyrosine phosphatase PTP1B and the adaptor Grb2; PTP1B paradoxically increases both PLD2 lipase activity and tyrosine phosphorylation.","method":"Co-immunoprecipitation, recombinant PTP1B treatment of immunoprecipitates, phosphatase activity assay","journal":"Biochemical and Biophysical Research Communications","confidence":"Medium","confidence_rationale":"Tier 3 — co-IP with enzymatic follow-up from single lab","pmids":["15896299"],"is_preprint":false},{"year":2008,"finding":"Cdk5 phosphorylates PLD2 at Ser134; this phosphorylation is required for EGF-dependent PLD2 activation and insulin secretion in pancreatic beta cells; PLD2-S134A mutant fails to show EGF-dependent activation.","method":"In vitro kinase assay, dominant-negative Cdk5, pharmacological inhibition (roscovitine), site-directed mutagenesis, insulin secretion assay","journal":"Cellular Signalling","confidence":"High","confidence_rationale":"Tier 1 — in vitro phosphorylation assay plus mutagenesis plus functional readout (insulin secretion)","pmids":["18625302"],"is_preprint":false},{"year":2011,"finding":"JAK3 phosphorylates PLD2 at Y415, activating it and enabling EGF-stimulated cancer cell invasion; JAK3 operates via a STAT-independent pathway to activate PLD2.","method":"siRNA knockdown, in vitro kinase assay, site-directed mutagenesis (Y415), Matrigel invasion assay","journal":"Journal of Molecular Biology","confidence":"High","confidence_rationale":"Tier 1/2 — in vitro phosphorylation plus mutagenesis plus functional invasion assay","pmids":["21414324"],"is_preprint":false},{"year":2011,"finding":"PLD2 has two CRIB motifs (CRIB-1 and CRIB-2) in and around the PH domain that mediate specific binding to Rac2; binding affinity Kd ~3 nM; PLD2 preferentially binds Rac2-GTP over Rac2-GDP; high Rac2-GTP acts as a termination signal inhibiting PLD2.","method":"Co-immunoprecipitation, FRET in living cells, in vitro binding with recombinant proteins, saturation binding assay, deletion mutagenesis","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro binding with Kd determination plus FRET validation in cells","pmids":["21378159"],"is_preprint":false},{"year":2012,"finding":"The PLD2 GEF catalytic site is located in the PX domain, formed by a hydrophobic pocket of residues Phe-107, Phe-129, Leu-166, Leu-173, and Arg-172; the PH domain region Ile-306–Ala-310 assists GEF activity by docking Rac2. PX domain alone is sufficient for GEF activity.","method":"In vitro GEF assay with GST fusion proteins and recombinant proteins, mutagenesis, chemotaxis and phagocytosis assays","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro GEF assay with systematic mutagenesis","pmids":["23035122"],"is_preprint":false},{"year":2009,"finding":"Phosphorylated PLD2 (via Grb2 binding) mediates lipase activity, whereas dephosphorylated PLD2 (associated with CD45 phosphatase) drives cell proliferation; key residues are Y179 and Y511. Affinity-purified PLD2 is activated by Grb2 and deactivated by CD45 in vitro.","method":"siRNA for CD45, overexpression of PLD2 mutants, in vitro activation/deactivation assay, proliferation markers (PCNA, p27, phospho-histone-3)","journal":"Biochemical and Biophysical Research Communications","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro assay plus mutagenesis from single lab","pmids":["19715678"],"is_preprint":false},{"year":2017,"finding":"PLD2-generated phosphatidic acid (PA) directly and specifically binds to KIF5B (kinesin-1 heavy chain) C-terminus; this PA-KIF5B interaction is required for vesicular association of KIF5B and surface localization of MT1-MMP, invadopodia formation, and breast cancer invasion/metastasis.","method":"PLD2 knockout mice (MMTV-Neu model), liposome pull-down screen, in vitro PA binding assay, KIF5B mutagenesis, live-cell imaging, invasion assay","journal":"Developmental Cell","confidence":"High","confidence_rationale":"Tier 1/2 — in vitro binding assay plus mutagenesis plus in vivo knockout model","pmids":["29033361"],"is_preprint":false},{"year":2018,"finding":"PLD2 (but not PLD1) is required for phagocytosis of aggregated oxidized LDL in macrophages; PLD2 and CD36 are mutually dependent for Agg-Ox-LDL uptake, and PLD2 couples phagocytosis with WASP, Grb2, and Actin complex formation.","method":"PLD2 knockout bone marrow-derived macrophages, PLD2-selective inhibitor, co-immunoprecipitation, phagocytosis assay","journal":"Journal of Leukocyte Biology","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout plus selective inhibitor plus co-IP, multiple orthogonal methods","pmids":["29656494"],"is_preprint":false},{"year":2016,"finding":"RalA activates PLD2 in endothelial cells; PLD2-generated PA facilitates caveolae-mediated endocytosis and fusion of caveolae with the plasma membrane, as shown by a PA biosensor colocalizing with Cav-1.","method":"siRNA knockdown of RalA and PLD2, co-immunoprecipitation, GFP-PASS PA biosensor, TIRF microscopy, fluorescent BSA uptake assay, dominant-negative PLD2","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including PA biosensor, dominant-negative, and functional uptake assay","pmids":["27510034"],"is_preprint":false},{"year":2019,"finding":"An acute decrease in plasma membrane tension activates PLD2 via disintegration of PLD2 nanodomains, leading to PA production, PI(4,5)P2- and F-actin-enriched dorsal ruffling, and subsequent macropinocytosis.","method":"Pharmacological membrane tension manipulation, confocal microscopy, PLD2 inhibition, lipid raft/nanodomain analysis, PA production measurement","journal":"Journal of Cell Science","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway defined with inhibitor and imaging, single lab","pmids":["31391241"],"is_preprint":false},{"year":2017,"finding":"PLD2 mediates phosphorylation of occludin via c-Src kinase and induces its proteasomal degradation, thereby disrupting intestinal epithelial tight junctions; intestinal epithelial-specific Pld2 knockout mice are protected from DSS-induced colitis.","method":"Conditional Pld2 knockout mice, Western blot for occludin and c-Src phosphorylation, proteasome inhibitor, pharmacological PLD2 inhibition","journal":"Scientific Reports","confidence":"High","confidence_rationale":"Tier 2 — conditional knockout plus mechanistic pathway identification (PLD2→c-Src→occludin degradation)","pmids":["28484281"],"is_preprint":false},{"year":2014,"finding":"PLD2 inhibitors FIPI and NFOT are mixed-kinetics inhibitors: FIPI acts at the S757 HKD2 catalytic site, whereas NFOT binds both the catalytic site (S757/S648) and an allosteric PIP2-binding pocket (R210/R212) in the PH domain.","method":"Enzyme kinetics analysis, site-directed mutagenesis, cancer cell invasion assay","journal":"Biochimica et Biophysica Acta","confidence":"High","confidence_rationale":"Tier 1/2 — enzyme kinetics plus mutagenesis defining active and allosteric sites","pmids":["25532944"],"is_preprint":false},{"year":2011,"finding":"PLD2 interacts with and activates the Fes/Fps tyrosine kinase during myeloid differentiation; PLD2 co-immunoprecipitates with Fes, and PA and PIP2 stimulate Fes activity; PLD2 overexpression shortens the time required for granulocytic differentiation of HL-60 cells.","method":"Co-immunoprecipitation, Fes kinase activity assay with PA/PIP2, siRNA, overexpression, differentiation time-course analysis","journal":"Journal of Biological Chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP plus in vitro kinase activation assay, single lab","pmids":["22094461"],"is_preprint":false},{"year":2019,"finding":"PLD2-generated PA directly binds IQGAP1 scaffold protein and promotes its plasma membrane recruitment; this PLD2-PA-IQGAP1 pathway is required for VSMC membrane ruffle formation and migration, and for injury-induced neointimal formation.","method":"PLD2 knockout mice (carotid ligation model), PA-IQGAP1 binding assay, IQGAP1 knockdown, PA-binding-deficient IQGAP1 mutant rescue, ruffle and migration assays","journal":"FASEB Journal","confidence":"High","confidence_rationale":"Tier 1/2 — in vitro binding assay plus mutagenesis plus in vivo knockout model","pmids":["30811216"],"is_preprint":false},{"year":2020,"finding":"PLD1 couples to TLR4/MyD88 signaling for M1 macrophage polarization, while PLD2 couples to IL-4R/JAK3 signaling for M2 macrophage polarization; LPS enhances TLR4-PLD1 interaction and IL-4 induces IL-4R-PLD2 association.","method":"Co-immunoprecipitation, PLD isoform-specific knockouts (Pld1-LyzCre, Pld2-LyzCre), cytokine assays, in vivo sepsis and injury models","journal":"Journal of Cellular Physiology","confidence":"High","confidence_rationale":"Tier 2 — isoform-specific genetic knockouts plus co-IP and in vivo models","pmids":["33368247"],"is_preprint":false},{"year":2003,"finding":"S100B-RAGE interaction triggers activation of PLD2, which mediates ROS production and augments Ang II-induced JAK2 phosphorylation and VSMC proliferation.","method":"PLD2 inhibition, overexpression, RAGE-dependent signaling assays, ROS measurement, JAK2 phosphorylation assay","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 3 — pharmacological inhibition and overexpression with functional signaling readout, single lab","pmids":["12941779"],"is_preprint":false},{"year":2021,"finding":"Adipocyte-specific PLD2 deletion augments thermogenesis by improving mitochondrial quality and quantity via p62; PLD2 inhibition confers resistance to diet-induced obesity and insulin resistance.","method":"Adipocyte-specific Pld2 knockout mice, PLD2 pharmacological inhibition, mitochondrial quality assays, p62 pathway analysis","journal":"Journal of Experimental Medicine","confidence":"Medium","confidence_rationale":"Tier 2 — conditional knockout plus mechanistic pathway (PLD2→p62→mitochondria), single lab","pmids":["34940790"],"is_preprint":false},{"year":2022,"finding":"PLD2 deletion protects against LPS-induced tight junction disruption in ALI via the PA/STAT3 axis; PLD2-generated PA increases STAT3 phosphorylation, which degrades endothelial tight junction proteins (claudin-5, occludin, ZO-1).","method":"PLD2 knockout mice, exogenous PA treatment, STAT3 inhibition, Western blot, permeability assays","journal":"International Immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic knockout plus PA rescue plus STAT3 inhibitor, single lab","pmids":["36700766"],"is_preprint":false},{"year":2007,"finding":"Mutation of PLD2-Y179F leads to increased AKT phosphorylation (T308 and S473) and DNA synthesis in a PI3K-dependent manner; activated Akt then phosphorylates PLD2 at T175 in a feedback loop; lipase activity (PA synthesis) is required for the DNA synthesis effect.","method":"Site-directed mutagenesis, PI3K inhibitor (LY294004), AKT phosphorylation assay, DNA synthesis (BrdU), ERK phosphorylation","journal":"Cellular Signalling","confidence":"Medium","confidence_rationale":"Tier 2 — mutagenesis plus pharmacological inhibition with mechanistic pathway defined, single lab","pmids":["18006275"],"is_preprint":false},{"year":2012,"finding":"The C-terminal domain (residues 578–933) of PLD2 interacts with CKIIβ subunit and promotes its ubiquitin-dependent proteasomal degradation; PLD2 relocates CKIIβ to the plasma membrane, and this function is independent of PLD2 catalytic activity.","method":"Co-immunoprecipitation, deletion mutants, overexpression/knockdown, proteasome inhibitor, immunofluorescence","journal":"BMB Reports","confidence":"Medium","confidence_rationale":"Tier 2 — deletion mutagenesis plus co-IP plus functional degradation assay, single lab","pmids":["21944249"],"is_preprint":false},{"year":2025,"finding":"PLD2 plays a role in retaining mutant KIT in the Golgi/TGN of GIST cells; KIT mut activates PLD2 through the PLCγ2–PKD2 cascade (independently of PI4KIIIβ), and PLD2 activity is required for γ-adaptin association with GGA1, mediating Golgi retention.","method":"PLD2 knockdown, PLD inhibitor (CAY10594), co-immunoprecipitation, immunofluorescence","journal":"bioRxiv (preprint)","confidence":"Medium","confidence_rationale":"Tier 2 — knockdown plus pharmacological inhibition plus co-IP defining pathway position; preprint","pmids":["bio_10.1101_2025.03.02.640696"],"is_preprint":true},{"year":2025,"finding":"Oleate enhances PLD2 S-acylation at Cys223 and Cys224, disrupting PLD2 lipid raft localization and increasing its colocalization with PIP2-enriched microdomains; this modulation activates both PLD2 lipase activity and its GEF activity toward Cdc42. Mutation of S-acylation sites abolishes PLD2-mediated Cdc42 activation and filopodia formation.","method":"Confocal microscopy, lipid raft isolation, S-acylation assay, site-directed mutagenesis (Cys223/224), GEF activity assay, filopodia quantification","journal":"Journal of Lipid Research","confidence":"High","confidence_rationale":"Tier 1 — S-acylation biochemistry plus mutagenesis plus GEF assay plus functional imaging","pmids":["41223946"],"is_preprint":false}],"current_model":"PLD2 is a plasma membrane-associated phospholipase that hydrolyzes phosphatidylcholine to generate phosphatidic acid (PA), and additionally functions as a guanine nucleotide exchange factor (GEF) for Rac2 and Cdc42 via its PX/PH domains; its activity is regulated by direct binding to PIP2, EGF receptor (phosphorylation at Y11), Grb2 (via Y169/Y179 SH2 interaction), Cdk5 (phosphorylation at S134), JAK3 (Y415), PKCα, and oleate-induced S-acylation (Cys223/224), while PA produced by PLD2 acts as a second messenger that binds KIF5B and IQGAP1 to regulate vesicle trafficking and cell migration, activates mTORC1 via a direct PLD2-raptor complex, and controls membrane tension-linked actin nucleation through mTORC2, collectively placing PLD2 as a central lipid signaling node regulating exosome biogenesis, cell migration, chemotaxis, phagocytosis, tight junction integrity, and macrophage polarization."},"narrative":{"teleology":[{"year":1998,"claim":"Establishing PLD2 as an EGF receptor-proximal signaling enzyme resolved how growth factor receptors directly regulate phospholipase D activity, revealing constitutive EGFR–PLD2 association and inhibitory Y11 phosphorylation as an activation switch.","evidence":"Co-IP, Y11F mutagenesis, and lipase activity assays in HEK293 cells","pmids":["9837959"],"confidence":"High","gaps":["Whether Y11 phosphorylation regulates PLD2 in vivo","Identity of the phosphatase that removes pY11"]},{"year":2000,"claim":"Demonstrating that PLD2 activity in vivo depends on local PIP2 generated by a physically associated Type Iα PIP kinase resolved how PLD2 is regulated at steady state and defined a feed-forward lipid signaling module.","evidence":"Reciprocal co-IP and in vivo activity assays in COS7 cells","pmids":["11032811"],"confidence":"High","gaps":["Structural basis of the PLD2–PIPKIα interaction","Whether other PIP kinase isoforms substitute"]},{"year":2000,"claim":"Identifying PKCα as a direct activator and physical interactor of PLD2 placed PLD2 downstream of calcium/DAG signaling, expanding the upstream inputs beyond receptor tyrosine kinases.","evidence":"Co-expression in Sf9 cells, IP, and membrane reconstitution assays","pmids":["10838164"],"confidence":"Medium","gaps":["PKCα phosphorylation site on PLD2 not identified","Single reconstitution system"]},{"year":2004,"claim":"Showing that alpha-synuclein inhibits PLD2 in vitro through its alpha-helical domain, with inhibition abolished by disease-relevant phosphorylations, linked PLD2 to potential Parkinson's disease-relevant lipid signaling.","evidence":"Reconstituted in vitro PLD2 activity assay with systematic alpha-synuclein mutants","pmids":["15033366"],"confidence":"High","gaps":["No in vivo or cellular validation of alpha-synuclein–PLD2 inhibition","Physiological relevance in neurons unclear"]},{"year":2006,"claim":"Identifying a direct PLD2–raptor complex mediated by a TOS-like motif and showing that both lipase activity and raptor binding are required for mTOR activation established PLD2 as a PA-dependent upstream activator of mTORC1.","evidence":"Co-IP, TOS motif mutagenesis, lipase-dead mutants, S6K1/4EBP1 phosphorylation in cells","pmids":["16837165"],"confidence":"High","gaps":["Structural detail of PA–mTOR interaction","Relative contribution of PLD2 vs PLD1 to mTOR in different tissues"]},{"year":2006,"claim":"Demonstrating that PLD2 lipase activity is essential for leukocyte chemotaxis and F-actin polarization answered whether PLD2 plays an effector role in immune cell migration.","evidence":"siRNA knockdown and lipase-dead mutant overexpression with chemotaxis and immunofluorescence in leukocytes","pmids":["16873675"],"confidence":"High","gaps":["Whether GEF activity also contributes to chemotaxis at this point was unknown"]},{"year":2006,"claim":"Mapping two SH2 binding sites (Y169, Y179) for Grb2 on PLD2, with Y169 controlling lipase activity and Y179 controlling PLD2 phosphorylation state, defined how the adaptor Grb2 serves as a master regulator coupling PLD2 to both enzymatic activation and Ras/MAPK proliferative signaling.","evidence":"GST pull-down, co-IP, point mutants, ERK phosphorylation, and DNA synthesis assays","pmids":["16407827","17276458","21419846"],"confidence":"High","gaps":["Whether both Grb2 SH2 sites are engaged simultaneously or sequentially","No structural model of PLD2–Grb2 complex"]},{"year":2008,"claim":"Identifying Cdk5-mediated S134 phosphorylation as necessary for EGF-dependent PLD2 activation placed PLD2 at an intersection of cell-cycle kinase and growth factor signaling, with functional consequence for insulin secretion.","evidence":"In vitro kinase assay, S134A mutagenesis, roscovitine inhibition, insulin secretion readout in beta cells","pmids":["18625302"],"confidence":"High","gaps":["Whether S134 phosphorylation modulates GEF activity","In vivo relevance in pancreatic islets"]},{"year":2011,"claim":"Discovering that PLD2 functions as a GEF for Rac2 through its PX/PH domains — independent of lipase activity — fundamentally revised PLD2's identity from a pure lipase to a bifunctional enzyme coordinating lipid signaling and Rho-family GTPase activation.","evidence":"Reconstituted in vitro GEF assay, FRET in living cells, Kd determination (~3 nM), systematic mutagenesis of CRIB motifs and PX domain","pmids":["22106281","21378159","23035122"],"confidence":"High","gaps":["No crystal structure of PX domain bound to Rac2","Whether PLD2 GEF activity is regulated by the same phosphorylations as lipase activity"]},{"year":2011,"claim":"Showing that JAK3 phosphorylates PLD2 at Y415 via a STAT-independent pathway to enable cancer cell invasion identified a new kinase input linking cytokine receptor signaling directly to PLD2-driven invasion.","evidence":"In vitro kinase assay, Y415 mutagenesis, siRNA, Matrigel invasion","pmids":["21414324"],"confidence":"High","gaps":["Whether JAK3–PLD2 axis operates in non-cancer cells","No in vivo validation"]},{"year":2014,"claim":"Demonstrating that ARF6 and PLD2 regulate syntenin-dependent exosome biogenesis by controlling ILV budding into MVBs revealed a lipid-driven mechanism for exosome production distinct from ESCRT-dependent pathways.","evidence":"siRNA, dominant-negative mutants, EM quantification, and functional rescue","pmids":["24637612"],"confidence":"High","gaps":["Whether PA itself or a PA metabolite drives ILV budding","Generalizability beyond syntenin cargo"]},{"year":2016,"claim":"Identifying PLD2 as a membrane tension sensor that limits actin nucleation through mTORC2 in neutrophils established a mechanotransduction pathway linking physical membrane properties to cell polarity and chemotaxis.","evidence":"Genetic knockout, optogenetic membrane tension manipulation, mathematical modeling, live-cell imaging","pmids":["27280401"],"confidence":"High","gaps":["How PLD2 senses tension mechanistically at the molecular level","Whether mTORC2 is the sole effector"]},{"year":2017,"claim":"Showing that PLD2-generated PA directly binds KIF5B and is required for MT1-MMP vesicle trafficking, invadopodia formation, and metastasis identified a specific PA effector mediating PLD2's pro-invasive function.","evidence":"PLD2 knockout mice (MMTV-Neu), liposome pull-down, KIF5B mutagenesis, in vitro binding","pmids":["29033361"],"confidence":"High","gaps":["PA-binding site on KIF5B not structurally resolved","Whether other kinesin family members also bind PA"]},{"year":2017,"claim":"Demonstrating that PLD2 disrupts tight junctions via c-Src-mediated occludin phosphorylation and proteasomal degradation, with intestinal Pld2 knockout mice protected from colitis, established PLD2 as a pathogenic mediator of epithelial barrier breakdown.","evidence":"Conditional Pld2 knockout mice, DSS colitis model, Western blot, proteasome inhibitor rescue","pmids":["28484281"],"confidence":"High","gaps":["How PLD2 activates c-Src","Whether PA or GEF activity mediates tight junction disruption"]},{"year":2019,"claim":"Identifying PA-dependent IQGAP1 plasma membrane recruitment as a PLD2 effector pathway in VSMC migration and neointimal formation provided a scaffold-mediated mechanism for PLD2's role in vascular remodeling.","evidence":"PLD2 knockout mice (carotid ligation), PA-IQGAP1 binding assay, PA-binding-deficient IQGAP1 mutant rescue","pmids":["30811216"],"confidence":"High","gaps":["Structural basis of PA–IQGAP1 binding","Whether PLD2–IQGAP1 axis operates in non-vascular contexts"]},{"year":2020,"claim":"Demonstrating isoform-specific coupling of PLD2 to IL-4R/JAK3 for M2 macrophage polarization (versus PLD1/TLR4 for M1) resolved how two PLD isoforms play opposing immunomodulatory roles.","evidence":"Isoform-specific macrophage-targeted knockouts (Pld2-LyzCre), co-IP, cytokine assays, in vivo sepsis and injury models","pmids":["33368247"],"confidence":"High","gaps":["Mechanistic basis of PLD2's selective coupling to IL-4R","Whether PLD2 GEF activity contributes to M2 polarization"]},{"year":2025,"claim":"Discovering that oleate-induced S-acylation at Cys223/224 redistributes PLD2 from lipid rafts to PIP2-enriched domains and activates both lipase and GEF (toward Cdc42) activities revealed a fatty acid–responsive post-translational switch coordinating PLD2's dual functions.","evidence":"S-acylation assay, Cys223/224 mutagenesis, lipid raft isolation, GEF activity assay, confocal microscopy","pmids":["41223946"],"confidence":"High","gaps":["Identity of the acyltransferase(s) responsible","Whether other fatty acids similarly regulate PLD2 S-acylation","In vivo metabolic relevance"]},{"year":null,"claim":"The structural basis of PLD2's bifunctional catalysis — how the same protein independently catalyzes phospholipid hydrolysis and GEF activity — remains unresolved, as no high-resolution structure of full-length PLD2 or its complexes with Rac2/Cdc42 is available.","evidence":"","pmids":[],"confidence":"High","gaps":["No crystal or cryo-EM structure of full-length PLD2","How lipase and GEF activities are coordinated in real time during signaling","Whether PLD2 tension sensing involves a conformational change or clustering mechanism"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[2,3,4,5,6,14,24]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[9,16,17,34]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[2,22,24]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3,8,10,22,26,34]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[0,19,21]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,5,11,14,15,27,31]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[0,19,21]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6,20,27]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[23,30]}],"complexes":["PLD2–PIPKIα complex","PLD2–raptor–mTORC1 complex","PLD2–Grb2 complex"],"partners":["GRB2","RAC2","EGFR","RPTOR","PIP5K1A","IQGAP1","KIF5B","JAK3"],"other_free_text":[]},"mechanistic_narrative":"PLD2 is a dual-function signaling enzyme that generates phosphatidic acid (PA) through phosphatidylcholine hydrolysis and independently acts as a guanine nucleotide exchange factor (GEF) for Rac2 and Cdc42 via its PX and PH domains, linking lipid signaling to cytoskeletal remodeling, vesicle trafficking, and cell migration [PMID:22106281, PMID:23035122, PMID:41223946]. PLD2 lipase activity is regulated by PIP2 generated through its physical interaction with Type Iα PIP kinase [PMID:11032811], and by phosphorylation events including EGF receptor-mediated Y11 phosphorylation [PMID:9837959], Cdk5-mediated S134 phosphorylation [PMID:18625302], JAK3-mediated Y415 phosphorylation [PMID:21414324], and Grb2 binding at Y169/Y179 [PMID:16407827], while oleate-induced S-acylation at Cys223/224 modulates both lipase and GEF activities by redistributing PLD2 from lipid rafts to PIP2-enriched membrane domains [PMID:41223946]. PA produced by PLD2 functions as a critical second messenger that activates mTORC1 through a direct PLD2–raptor complex [PMID:16837165], recruits KIF5B to vesicles for MT1-MMP surface delivery and cancer invasion [PMID:29033361], binds IQGAP1 to drive cell migration [PMID:30811216], and regulates tight junction integrity via c-Src-dependent occludin degradation [PMID:28484281]. PLD2 also serves as a plasma membrane tension sensor that controls actin nucleation through mTORC2 in neutrophil chemotaxis [PMID:27280401], mediates ARF6-dependent exosome biogenesis [PMID:24637612], and couples to IL-4R/JAK3 signaling to promote M2 macrophage polarization [PMID:33368247]."},"prefetch_data":{"uniprot":{"accession":"O14939","full_name":"Phospholipase D2","aliases":["Choline phosphatase 2","PLD1C","Phosphatidylcholine-hydrolyzing phospholipase D2"],"length_aa":933,"mass_kda":106.0,"function":"Function as phospholipase selective for phosphatidylcholine (PubMed:9582313). May have a role in signal-induced cytoskeletal regulation and/or endocytosis (By similarity)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/O14939/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PLD2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000129219","cell_line_id":"CID000170","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"membrane","grade":1},{"compartment":"vesicles","grade":1}],"interactors":[{"gene":"FKBP5","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID000170","total_profiled":1310},"omim":[{"mim_id":"621519","title":"SCAFFOLDING CK1-ANCHORING PROTEIN B; SACK1B","url":"https://www.omim.org/entry/621519"},{"mim_id":"612334","title":"N-ACYL PHOSPHATIDYLETHANOLAMINE-HYDROLYZING PHOSPHOLIPASE D; NAPEPLD","url":"https://www.omim.org/entry/612334"},{"mim_id":"603122","title":"DEDICATOR OF CYTOKINESIS 2; DOCK2","url":"https://www.omim.org/entry/603122"},{"mim_id":"602384","title":"PHOSPHOLIPASE D2; PLD2","url":"https://www.omim.org/entry/602384"},{"mim_id":"602382","title":"PHOSPHOLIPASE D1, PHOSPHATIDYLCHOLINE-SPECIFIC; PLD1","url":"https://www.omim.org/entry/602382"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"esophagus","ntpm":62.1}],"url":"https://www.proteinatlas.org/search/PLD2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"O14939","domains":[{"cath_id":"3.30.1520.10","chopping":"38-76_86-117_162-198","consensus_level":"medium","plddt":87.7857,"start":38,"end":198},{"cath_id":"2.30.29.30","chopping":"203-218_231-320","consensus_level":"high","plddt":90.1025,"start":203,"end":320},{"cath_id":"3.30.870.10","chopping":"331-477_501-565","consensus_level":"medium","plddt":96.7864,"start":331,"end":565}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O14939","model_url":"https://alphafold.ebi.ac.uk/files/AF-O14939-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O14939-F1-predicted_aligned_error_v6.png","plddt_mean":88.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PLD2","jax_strain_url":"https://www.jax.org/strain/search?query=PLD2"},"sequence":{"accession":"O14939","fasta_url":"https://rest.uniprot.org/uniprotkb/O14939.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O14939/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O14939"}},"corpus_meta":[{"pmid":"24637612","id":"PMC_24637612","title":"Syntenin-ALIX exosome biogenesis and budding into multivesicular bodies are controlled by ARF6 and PLD2.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/24637612","citation_count":451,"is_preprint":false},{"pmid":"27280401","id":"PMC_27280401","title":"Membrane Tension Acts Through PLD2 and mTORC2 to Limit Actin Network Assembly During Neutrophil Migration.","date":"2016","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/27280401","citation_count":147,"is_preprint":false},{"pmid":"11032811","id":"PMC_11032811","title":"Interaction of the type Ialpha PIPkinase with phospholipase D: a role for the local generation of phosphatidylinositol 4, 5-bisphosphate in the regulation of PLD2 activity.","date":"2000","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11032811","citation_count":107,"is_preprint":false},{"pmid":"9837959","id":"PMC_9837959","title":"PLD2 complexes with the EGF receptor and undergoes tyrosine phosphorylation at a single site upon agonist stimulation.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9837959","citation_count":101,"is_preprint":false},{"pmid":"9761774","id":"PMC_9761774","title":"Characterization of human PLD2 and the analysis of PLD isoform splice variants.","date":"1998","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/9761774","citation_count":101,"is_preprint":false},{"pmid":"15033366","id":"PMC_15033366","title":"Structural determinants of PLD2 inhibition by alpha-synuclein.","date":"2004","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15033366","citation_count":83,"is_preprint":false},{"pmid":"16873675","id":"PMC_16873675","title":"Phagocyte cell migration is mediated by phospholipases PLD1 and PLD2.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16873675","citation_count":81,"is_preprint":false},{"pmid":"12941779","id":"PMC_12941779","title":"S100B-RAGE-mediated augmentation of angiotensin II-induced activation of JAK2 in vascular smooth muscle cells is dependent on PLD2.","date":"2003","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/12941779","citation_count":80,"is_preprint":false},{"pmid":"10838164","id":"PMC_10838164","title":"Regulation of human PLD1 and PLD2 by calcium and protein kinase C.","date":"2000","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/10838164","citation_count":59,"is_preprint":false},{"pmid":"14704231","id":"PMC_14704231","title":"Localization of VEGFR-2 and PLD2 in endothelial caveolae is involved in VEGF-induced phosphorylation of MEK and ERK.","date":"2004","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/14704231","citation_count":54,"is_preprint":false},{"pmid":"29033361","id":"PMC_29033361","title":"Binding of PLD2-Generated Phosphatidic Acid to KIF5B Promotes MT1-MMP Surface Trafficking and Lung Metastasis of Mouse Breast Cancer Cells.","date":"2017","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/29033361","citation_count":51,"is_preprint":false},{"pmid":"29656494","id":"PMC_29656494","title":"Oxidized LDL phagocytosis during foam cell formation in atherosclerotic plaques relies on a PLD2-CD36 functional interdependence.","date":"2018","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/29656494","citation_count":48,"is_preprint":false},{"pmid":"24270883","id":"PMC_24270883","title":"MicroRNA-203 inhibits the proliferation and invasion of U251 glioblastoma cells by directly targeting PLD2.","date":"2013","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/24270883","citation_count":48,"is_preprint":false},{"pmid":"16837165","id":"PMC_16837165","title":"PLD2 forms a functional complex with mTOR/raptor to transduce mitogenic signals.","date":"2006","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/16837165","citation_count":46,"is_preprint":false},{"pmid":"22106281","id":"PMC_22106281","title":"Phospholipase D2 (PLD2) is a guanine nucleotide exchange factor (GEF) for the GTPase Rac2.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22106281","citation_count":42,"is_preprint":false},{"pmid":"21419846","id":"PMC_21419846","title":"The mechanism of cell membrane ruffling relies on a phospholipase D2 (PLD2), Grb2 and Rac2 association.","date":"2011","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/21419846","citation_count":39,"is_preprint":false},{"pmid":"16407827","id":"PMC_16407827","title":"The elucidation of novel SH2 binding sites on PLD2.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16407827","citation_count":38,"is_preprint":false},{"pmid":"21610093","id":"PMC_21610093","title":"PLD1 rather than PLD2 regulates phorbol-ester-, adhesion-dependent and Fc{gamma}-receptor-stimulated ROS production in neutrophils.","date":"2011","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/21610093","citation_count":34,"is_preprint":false},{"pmid":"28484281","id":"PMC_28484281","title":"Intestinal Epithelial Cell-Specific Deletion of PLD2 Alleviates DSS-Induced Colitis by Regulating Occludin.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28484281","citation_count":33,"is_preprint":false},{"pmid":"23238254","id":"PMC_23238254","title":"Serum deprivation confers the MDA-MB-231 breast cancer line with an EGFR/JAK3/PLD2 system that maximizes cancer cell invasion.","date":"2012","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23238254","citation_count":33,"is_preprint":false},{"pmid":"31391241","id":"PMC_31391241","title":"An acute decrease in plasma membrane tension induces macropinocytosis via PLD2 activation.","date":"2019","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/31391241","citation_count":32,"is_preprint":false},{"pmid":"17276458","id":"PMC_17276458","title":"The Grb2/PLD2 interaction is essential for lipase activity, intracellular localization and signaling in response to EGF.","date":"2007","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17276458","citation_count":32,"is_preprint":false},{"pmid":"27510034","id":"PMC_27510034","title":"Phosphatidic Acid Produced by RalA-activated PLD2 Stimulates Caveolae-mediated Endocytosis and Trafficking in Endothelial Cells.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27510034","citation_count":31,"is_preprint":false},{"pmid":"21740967","id":"PMC_21740967","title":"The exquisite regulation of PLD2 by a wealth of interacting proteins: S6K, Grb2, Sos, WASp and Rac2 (and a surprise discovery: PLD2 is a GEF).","date":"2011","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/21740967","citation_count":31,"is_preprint":false},{"pmid":"11341968","id":"PMC_11341968","title":"Regulation of phospholipase D (PLD) in growth plate chondrocytes by 24R,25-(OH)2D3 is dependent on cell maturation state (resting zone cells) and is specific to the PLD2 isoform.","date":"2001","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/11341968","citation_count":30,"is_preprint":false},{"pmid":"18625302","id":"PMC_18625302","title":"Cdk5 phosphorylates PLD2 to mediate EGF-dependent insulin secretion.","date":"2008","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/18625302","citation_count":30,"is_preprint":false},{"pmid":"21414324","id":"PMC_21414324","title":"Cell invasion of highly metastatic MTLn3 cancer cells is dependent on phospholipase D2 (PLD2) and Janus kinase 3 (JAK3).","date":"2011","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21414324","citation_count":25,"is_preprint":false},{"pmid":"21378159","id":"PMC_21378159","title":"Evidence for two CRIB domains in phospholipase D2 (PLD2) that the enzyme uses to specifically bind to the small GTPase Rac2.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21378159","citation_count":24,"is_preprint":false},{"pmid":"33368247","id":"PMC_33368247","title":"PLD1 and PLD2 differentially regulate the balance of macrophage polarization in inflammation and tissue injury.","date":"2020","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33368247","citation_count":23,"is_preprint":false},{"pmid":"9533024","id":"PMC_9533024","title":"Molecular cloning and chromosome mapping of rat phospholipase D genes, Pld1a, Pld1b and Pld2.","date":"1997","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9533024","citation_count":23,"is_preprint":false},{"pmid":"25532944","id":"PMC_25532944","title":"Two sites of action for PLD2 inhibitors: The enzyme catalytic center and an allosteric, phosphoinositide biding pocket.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25532944","citation_count":22,"is_preprint":false},{"pmid":"11341962","id":"PMC_11341962","title":"Presence of a phospholipase D (PLD) distinct from PLD1 or PLD2 in human neutrophils: immunobiochemical characterization and initial purification.","date":"2001","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/11341962","citation_count":20,"is_preprint":false},{"pmid":"38403587","id":"PMC_38403587","title":"Essential role of PLD2 in hypoxia-induced stemness and therapy resistance in ovarian tumors.","date":"2024","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/38403587","citation_count":19,"is_preprint":false},{"pmid":"36700766","id":"PMC_36700766","title":"PLD2 deletion alleviates disruption of tight junctions in sepsis-induced ALI by regulating PA/STAT3 phosphorylation pathway.","date":"2022","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36700766","citation_count":18,"is_preprint":false},{"pmid":"16024570","id":"PMC_16024570","title":"ANG II-induced neointimal growth is mediated via cPLA2- and PLD2-activated Akt in balloon-injured rat carotid artery.","date":"2005","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16024570","citation_count":18,"is_preprint":false},{"pmid":"23261454","id":"PMC_23261454","title":"TLR2 stimulates ABCA1 expression via PKC-η and PLD2 pathway.","date":"2012","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23261454","citation_count":18,"is_preprint":false},{"pmid":"23667561","id":"PMC_23667561","title":"Coronin 1B regulates S1P-induced human lung endothelial cell chemotaxis: role of PLD2, protein kinase C and Rac1 signal transduction.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23667561","citation_count":18,"is_preprint":false},{"pmid":"18006275","id":"PMC_18006275","title":"Mutation of Y179 on phospholipase D2 (PLD2) upregulates DNA synthesis in a PI3K-and Akt-dependent manner.","date":"2007","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/18006275","citation_count":17,"is_preprint":false},{"pmid":"15896299","id":"PMC_15896299","title":"The uncovering of a novel regulatory mechanism for PLD2: formation of a ternary complex with protein tyrosine phosphatase PTP1B and growth factor receptor-bound protein GRB2.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15896299","citation_count":17,"is_preprint":false},{"pmid":"27721573","id":"PMC_27721573","title":"Blockade of PLD2 Ameliorates Intestinal Mucosal Inflammation of Inflammatory Bowel Disease.","date":"2016","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/27721573","citation_count":16,"is_preprint":false},{"pmid":"19715678","id":"PMC_19715678","title":"PLD2 has both enzymatic and cell proliferation-inducing capabilities, that are differentially regulated by phosphorylation and dephosphorylation.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19715678","citation_count":14,"is_preprint":false},{"pmid":"28656282","id":"PMC_28656282","title":"AQP3 small interfering RNA and PLD2 small interfering RNA inhibit the proliferation and promote the apoptosis of squamous cell carcinoma.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28656282","citation_count":14,"is_preprint":false},{"pmid":"23035122","id":"PMC_23035122","title":"Identification of the catalytic site of phospholipase D2 (PLD2) newly described guanine nucleotide exchange factor activity.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23035122","citation_count":13,"is_preprint":false},{"pmid":"30811216","id":"PMC_30811216","title":"Phosphatidic acid generated by PLD2 promotes the plasma membrane recruitment of IQGAP1 and neointima formation.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30811216","citation_count":12,"is_preprint":false},{"pmid":"22750546","id":"PMC_22750546","title":"Biochemical and cellular implications of a dual lipase-GEF function of phospholipase D2 (PLD2).","date":"2012","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/22750546","citation_count":11,"is_preprint":false},{"pmid":"38630134","id":"PMC_38630134","title":"PLD2 deletion ameliorates sepsis-induced cardiomyopathy by suppressing cardiomyocyte pyroptosis via the NLRP3/caspase 1/GSDMD pathway.","date":"2024","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/38630134","citation_count":11,"is_preprint":false},{"pmid":"17083197","id":"PMC_17083197","title":"Human recombinant PLD2 can repress p65 activity of guinea pigs of chronic asthma in vivo.","date":"2006","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17083197","citation_count":9,"is_preprint":false},{"pmid":"34940790","id":"PMC_34940790","title":"Targeting PLD2 in adipocytes augments adaptive thermogenesis by improving mitochondrial quality and quantity in mice.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34940790","citation_count":8,"is_preprint":false},{"pmid":"32205175","id":"PMC_32205175","title":"HIF1α/PLD2 axis linked to glycolysis induces T-cell immunity in oral lichen planus.","date":"2020","source":"Biochimica et biophysica acta. General subjects","url":"https://pubmed.ncbi.nlm.nih.gov/32205175","citation_count":8,"is_preprint":false},{"pmid":"22094461","id":"PMC_22094461","title":"Phospholipase D2 (PLD2) shortens the time required for myeloid leukemic cell differentiation: mechanism of action.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22094461","citation_count":8,"is_preprint":false},{"pmid":"37691020","id":"PMC_37691020","title":"OGD/R-induced ferroptosis and pyroptosis in retinal pigment epithelium cells: Role of PLD1 and PLD2 modulation.","date":"2023","source":"Cell biochemistry and function","url":"https://pubmed.ncbi.nlm.nih.gov/37691020","citation_count":7,"is_preprint":false},{"pmid":"32687545","id":"PMC_32687545","title":"PLD2-PI(4,5)P2 interactions in fluid phase membranes: Structural modeling and molecular dynamics simulations.","date":"2020","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/32687545","citation_count":7,"is_preprint":false},{"pmid":"22858691","id":"PMC_22858691","title":"Structure analysis between the SWAP-70 RHO-GEF and the newly described PLD2-GEF.","date":"2012","source":"Small GTPases","url":"https://pubmed.ncbi.nlm.nih.gov/22858691","citation_count":6,"is_preprint":false},{"pmid":"38706911","id":"PMC_38706911","title":"Decreased Expression of PLD2 Promotes EMT in Colorectal Cancer Invasion and Metastasis.","date":"2024","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38706911","citation_count":5,"is_preprint":false},{"pmid":"22426721","id":"PMC_22426721","title":"Cloning of PLD2 from baculovirus for studies in inflammatory responses.","date":"2012","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/22426721","citation_count":5,"is_preprint":false},{"pmid":"23649737","id":"PMC_23649737","title":"Analysis of non-synonymous single-nucleotide polymorphisms and population variability of PLD2 gene associated with hypertension.","date":"2013","source":"International journal of bioinformatics research and applications","url":"https://pubmed.ncbi.nlm.nih.gov/23649737","citation_count":4,"is_preprint":false},{"pmid":"39461986","id":"PMC_39461986","title":"The molecular mechanism of PLD2-mediated regulation of apoptosis and cell edema in pancreatic cells via the Nrf2/NF-κB pathway.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39461986","citation_count":4,"is_preprint":false},{"pmid":"37455419","id":"PMC_37455419","title":"Importance of PLD2 in an IL-23 driven psoriasiform dermatitis model and potential link to human psoriasis.","date":"2023","source":"The Journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/37455419","citation_count":3,"is_preprint":false},{"pmid":"28533957","id":"PMC_28533957","title":"PLD2 regulates microtubule stability and spindle migration in mouse oocytes during meiotic division.","date":"2017","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/28533957","citation_count":3,"is_preprint":false},{"pmid":"38563085","id":"PMC_38563085","title":"β-Hydroxy-β-methylbutyrate (HMB) leads to phospholipase D2 (PLD2) activation and alters circadian rhythms in myotubes.","date":"2024","source":"Food & function","url":"https://pubmed.ncbi.nlm.nih.gov/38563085","citation_count":3,"is_preprint":false},{"pmid":"21944249","id":"PMC_21944249","title":"The C-terminal domain of PLD2 participates in degradation of protein kinase CKII β subunit in human colorectal carcinoma cells.","date":"2011","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/21944249","citation_count":3,"is_preprint":false},{"pmid":"38703555","id":"PMC_38703555","title":"PLD2 deficiency alleviates endothelial glycocalyx degradation in LPS-induced ARDS/ALI.","date":"2024","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/38703555","citation_count":3,"is_preprint":false},{"pmid":"32524116","id":"PMC_32524116","title":"[Effect of mi-138 targeting PLD2 gene on proliferation and migration of oral cancer cells].","date":"2020","source":"Shanghai kou qiang yi xue = Shanghai journal of stomatology","url":"https://pubmed.ncbi.nlm.nih.gov/32524116","citation_count":1,"is_preprint":false},{"pmid":"41177242","id":"PMC_41177242","title":"Jieyu Wuwei Sinisan formula alleviates depression-like behaviors in CUMS mice by regulating synaptic plasticity through PLD2 pathway.","date":"2025","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/41177242","citation_count":0,"is_preprint":false},{"pmid":"41223946","id":"PMC_41223946","title":"Oleate activates PLD2 lipase and GEF activity by modulating membrane microdomain dynamics via S-acylation.","date":"2025","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/41223946","citation_count":0,"is_preprint":false},{"pmid":"41449865","id":"PMC_41449865","title":"Astragaloside IV Alleviates Colorectal Cancer Metastases by Regulating RALY/PLD2 Axis and Inhibiting Tumoral Exosome Biogenesis.","date":"2025","source":"Phytotherapy research : PTR","url":"https://pubmed.ncbi.nlm.nih.gov/41449865","citation_count":0,"is_preprint":false},{"pmid":"41308722","id":"PMC_41308722","title":"Optimizing functional recovery after acute ischemic stroke through intensity and frequency of rehabilitation: The critical role of HIF-1α/PLD2/mTOR signaling mechanisms.","date":"2025","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/41308722","citation_count":0,"is_preprint":false},{"pmid":"39692536","id":"PMC_39692536","title":"Differential Control of T-Cell Subsets by Recombinant Human PLD2 in a Mouse Model of Allergic Asthma.","date":"2024","source":"Immunological investigations","url":"https://pubmed.ncbi.nlm.nih.gov/39692536","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.03.02.640696","title":"Golgi retention of KIT in gastrointestinal stromal tumour cells is phospholipase D activity-dependent","date":"2025-03-03","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.02.640696","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":38157,"output_tokens":7867,"usd":0.116238},"stage2":{"model":"claude-opus-4-6","input_tokens":11695,"output_tokens":4184,"usd":0.244613},"total_usd":0.360851,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"ARF6 and its effector PLD2 regulate syntenin exosome biogenesis by controlling the budding of intraluminal vesicles (ILVs) into multivesicular bodies (MVBs), identifying a novel pathway for ILV budding and exosome production.\",\n      \"method\": \"siRNA knockdown, dominant-negative mutants, electron microscopy, functional rescue experiments\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (siRNA, dominant-negatives, EM), replicated mechanistic epistasis in a high-citation paper\",\n      \"pmids\": [\"24637612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Elevated membrane tension acts through PLD2 and mTORC2 to limit actin nucleation in neutrophils; loss of this pathway causes larger leading edges, higher membrane tension, and defective chemotaxis.\",\n      \"method\": \"Genetic knockdown/knockout, optogenetic membrane tension manipulation, mathematical modeling, live-cell imaging\",\n      \"journal\": \"PLoS Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods with clean loss-of-function phenotype and pathway placement, high citation count\",\n      \"pmids\": [\"27280401\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PLD2 physically interacts with Type Iα PIPkinase; PLD2 recruits PIPkinase to its intracellular location and its activity in vivo is regulated solely by local PtdIns(4,5)P2 levels generated by this kinase.\",\n      \"method\": \"Co-immunoprecipitation, overexpression in COS7 cells, in vivo activity assays\",\n      \"journal\": \"The EMBO Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP plus functional activity rescue, high citation count\",\n      \"pmids\": [\"11032811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"PLD2 (but not PLD1) constitutively associates with the EGF receptor in a ligand-independent manner and is tyrosine-phosphorylated at Tyr-11 upon EGF receptor activation; mutation Y11F enhances basal PLD2 activity ~2-fold.\",\n      \"method\": \"Co-immunoprecipitation, site-directed mutagenesis, transient transfection in HEK293 cells, lipase activity assay\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — mutagenesis plus co-IP plus activity assay, high citation count\",\n      \"pmids\": [\"9837959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Alpha-synuclein inhibits PLD2 in vitro; inhibition requires an alpha-helical conformation stabilized by exon 4 residues and residues in exon 6 (C-terminal 130–140); phosphorylation at S129, Y125, or Y136 abolishes PLD2 inhibition by alpha-synuclein.\",\n      \"method\": \"In vitro PLD2 activity assay with recombinant proteins, deletion and point mutants of alpha-synuclein, phosphomimetic mutations\",\n      \"journal\": \"Journal of Molecular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro with systematic mutagenesis\",\n      \"pmids\": [\"15033366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PLD2 forms a functional complex with mTOR/raptor via a TOS-like motif (Phe-Glu-Val-Gln-Val, aa 265–269) in PLD2; PLD2-dependent mTOR activation requires both binding to raptor and lipase activity, as lipase-inactive PLD2 cannot activate mTOR despite binding raptor.\",\n      \"method\": \"siRNA knockdown, co-immunoprecipitation, site-directed mutagenesis, S6K1/4EBP1 phosphorylation assays\",\n      \"journal\": \"Cellular Signalling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP, mutagenesis, and functional rescue with defined mechanistic pathway\",\n      \"pmids\": [\"16837165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PLD2 is required for leukocyte chemotaxis; PLD2 enzymatic activity mediates ENA-78/CXCR-2-induced chemotaxis, and both PLD2 isoforms associate with cell polarity and F-actin polymerization in response to IL-8.\",\n      \"method\": \"siRNA knockdown, overexpression of lipase-inactive mutant, in vitro chemotaxis assay, immunofluorescence microscopy\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — lipase-dead mutant plus siRNA with defined phenotypic readout\",\n      \"pmids\": [\"16873675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PLD2 can be activated by calcium-mobilizing agonists and by co-expression with PKCα (but not PKCδ) in Sf9 cells; PLD1 and PLD2 physically associate with PKC isoforms and can be stimulated by calmodulin and PKCα-enriched cytosol in reconstitution assays.\",\n      \"method\": \"Co-expression in Sf9 cells, immunoprecipitation, membrane reconstitution assays, PtdEth production assay\",\n      \"journal\": \"Biochimica et Biophysica Acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP and functional assay from single lab\",\n      \"pmids\": [\"10838164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"VEGFR-2 and PLD2 co-localize in endothelial caveolae; VEGF activates PLD via VEGFR-2/PKC-δ, and PLD-generated phosphatidic acid is required for VEGF-induced MEK/ERK phosphorylation and endothelial cell proliferation.\",\n      \"method\": \"Subcellular fractionation, 1-butanol inhibition, phosphatidic acid rescue, pharmacological inhibitors, caveolae disruption with MβCD\",\n      \"journal\": \"American Journal of Physiology Heart and Circulatory Physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — fractionation plus pharmacological inhibition with functional rescue\",\n      \"pmids\": [\"14704231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PLD2 directly binds to Rac2 and functions as a guanine nucleotide exchange factor (GEF), promoting GDP dissociation (~72% decrease) and GTP association (~300% increase) on Rac2; GEF activity is independent of lipase activity. The PLD2-Rac2 interaction involves CRIB-region residues 263–266 in the PH domain and the PX domain of PLD2, and Switch-1 residue N17 of Rac2.\",\n      \"method\": \"In vitro GEF assay with recombinant proteins, co-immunoprecipitation, site-directed mutagenesis, FRET in living cells, cell functional assays (adhesion, chemotaxis, phagocytosis)\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro GEF assay plus mutagenesis plus FRET in living cells\",\n      \"pmids\": [\"22106281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PLD2 co-localizes with Grb2 and actin-rich membrane protrusions in macrophages; PLD2 interacts with Grb2 via Y169 (SH2 domain), which enhances PLD activity and, together with Rac2, drives actin polymerization and membrane ruffle formation.\",\n      \"method\": \"YFP/CFP fluorescent chimeras, immunoprecipitation, site-directed mutagenesis (Y169F, Grb2-R86K), overexpression, actin polymerization assay\",\n      \"journal\": \"Cellular Signalling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP, mutagenesis, and live-cell imaging with functional phenotype\",\n      \"pmids\": [\"21419846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PLD2 residues Y169 and Y179 form two SH2 binding sites for Grb2: Y169 modulates enzymatic activity and Y179 regulates tyrosine phosphorylation of PLD2; Y169 also mediates cellular proliferation through Ras/MAPK when Y179 regulation is released.\",\n      \"method\": \"GST pull-down, co-immunoprecipitation, deletion and point mutants, DNA synthesis assay, ERK phosphorylation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple mutagenesis studies with orthogonal functional readouts\",\n      \"pmids\": [\"16407827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Grb2 is essential for PLD2 activity in vivo; Grb2 interacts with PLD2 via its SH2 domain (PLD2-Y169), and after EGF stimulation, Grb2 re-localizes PLD2 to Golgi-like perinuclear structures via its SH2 domain.\",\n      \"method\": \"shRNA stable knockdown, rescue with shRNA-resistant Grb2, co-immunoprecipitation, immunofluorescence microscopy, primary HUVEC imaging\",\n      \"journal\": \"Journal of Molecular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — shRNA knockdown plus rescue plus localization imaging with functional consequence\",\n      \"pmids\": [\"17276458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PLD2 exists in a ternary complex with protein tyrosine phosphatase PTP1B and the adaptor Grb2; PTP1B paradoxically increases both PLD2 lipase activity and tyrosine phosphorylation.\",\n      \"method\": \"Co-immunoprecipitation, recombinant PTP1B treatment of immunoprecipitates, phosphatase activity assay\",\n      \"journal\": \"Biochemical and Biophysical Research Communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — co-IP with enzymatic follow-up from single lab\",\n      \"pmids\": [\"15896299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Cdk5 phosphorylates PLD2 at Ser134; this phosphorylation is required for EGF-dependent PLD2 activation and insulin secretion in pancreatic beta cells; PLD2-S134A mutant fails to show EGF-dependent activation.\",\n      \"method\": \"In vitro kinase assay, dominant-negative Cdk5, pharmacological inhibition (roscovitine), site-directed mutagenesis, insulin secretion assay\",\n      \"journal\": \"Cellular Signalling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro phosphorylation assay plus mutagenesis plus functional readout (insulin secretion)\",\n      \"pmids\": [\"18625302\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"JAK3 phosphorylates PLD2 at Y415, activating it and enabling EGF-stimulated cancer cell invasion; JAK3 operates via a STAT-independent pathway to activate PLD2.\",\n      \"method\": \"siRNA knockdown, in vitro kinase assay, site-directed mutagenesis (Y415), Matrigel invasion assay\",\n      \"journal\": \"Journal of Molecular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — in vitro phosphorylation plus mutagenesis plus functional invasion assay\",\n      \"pmids\": [\"21414324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PLD2 has two CRIB motifs (CRIB-1 and CRIB-2) in and around the PH domain that mediate specific binding to Rac2; binding affinity Kd ~3 nM; PLD2 preferentially binds Rac2-GTP over Rac2-GDP; high Rac2-GTP acts as a termination signal inhibiting PLD2.\",\n      \"method\": \"Co-immunoprecipitation, FRET in living cells, in vitro binding with recombinant proteins, saturation binding assay, deletion mutagenesis\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro binding with Kd determination plus FRET validation in cells\",\n      \"pmids\": [\"21378159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The PLD2 GEF catalytic site is located in the PX domain, formed by a hydrophobic pocket of residues Phe-107, Phe-129, Leu-166, Leu-173, and Arg-172; the PH domain region Ile-306–Ala-310 assists GEF activity by docking Rac2. PX domain alone is sufficient for GEF activity.\",\n      \"method\": \"In vitro GEF assay with GST fusion proteins and recombinant proteins, mutagenesis, chemotaxis and phagocytosis assays\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro GEF assay with systematic mutagenesis\",\n      \"pmids\": [\"23035122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Phosphorylated PLD2 (via Grb2 binding) mediates lipase activity, whereas dephosphorylated PLD2 (associated with CD45 phosphatase) drives cell proliferation; key residues are Y179 and Y511. Affinity-purified PLD2 is activated by Grb2 and deactivated by CD45 in vitro.\",\n      \"method\": \"siRNA for CD45, overexpression of PLD2 mutants, in vitro activation/deactivation assay, proliferation markers (PCNA, p27, phospho-histone-3)\",\n      \"journal\": \"Biochemical and Biophysical Research Communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro assay plus mutagenesis from single lab\",\n      \"pmids\": [\"19715678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PLD2-generated phosphatidic acid (PA) directly and specifically binds to KIF5B (kinesin-1 heavy chain) C-terminus; this PA-KIF5B interaction is required for vesicular association of KIF5B and surface localization of MT1-MMP, invadopodia formation, and breast cancer invasion/metastasis.\",\n      \"method\": \"PLD2 knockout mice (MMTV-Neu model), liposome pull-down screen, in vitro PA binding assay, KIF5B mutagenesis, live-cell imaging, invasion assay\",\n      \"journal\": \"Developmental Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — in vitro binding assay plus mutagenesis plus in vivo knockout model\",\n      \"pmids\": [\"29033361\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PLD2 (but not PLD1) is required for phagocytosis of aggregated oxidized LDL in macrophages; PLD2 and CD36 are mutually dependent for Agg-Ox-LDL uptake, and PLD2 couples phagocytosis with WASP, Grb2, and Actin complex formation.\",\n      \"method\": \"PLD2 knockout bone marrow-derived macrophages, PLD2-selective inhibitor, co-immunoprecipitation, phagocytosis assay\",\n      \"journal\": \"Journal of Leukocyte Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout plus selective inhibitor plus co-IP, multiple orthogonal methods\",\n      \"pmids\": [\"29656494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"RalA activates PLD2 in endothelial cells; PLD2-generated PA facilitates caveolae-mediated endocytosis and fusion of caveolae with the plasma membrane, as shown by a PA biosensor colocalizing with Cav-1.\",\n      \"method\": \"siRNA knockdown of RalA and PLD2, co-immunoprecipitation, GFP-PASS PA biosensor, TIRF microscopy, fluorescent BSA uptake assay, dominant-negative PLD2\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including PA biosensor, dominant-negative, and functional uptake assay\",\n      \"pmids\": [\"27510034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"An acute decrease in plasma membrane tension activates PLD2 via disintegration of PLD2 nanodomains, leading to PA production, PI(4,5)P2- and F-actin-enriched dorsal ruffling, and subsequent macropinocytosis.\",\n      \"method\": \"Pharmacological membrane tension manipulation, confocal microscopy, PLD2 inhibition, lipid raft/nanodomain analysis, PA production measurement\",\n      \"journal\": \"Journal of Cell Science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway defined with inhibitor and imaging, single lab\",\n      \"pmids\": [\"31391241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PLD2 mediates phosphorylation of occludin via c-Src kinase and induces its proteasomal degradation, thereby disrupting intestinal epithelial tight junctions; intestinal epithelial-specific Pld2 knockout mice are protected from DSS-induced colitis.\",\n      \"method\": \"Conditional Pld2 knockout mice, Western blot for occludin and c-Src phosphorylation, proteasome inhibitor, pharmacological PLD2 inhibition\",\n      \"journal\": \"Scientific Reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional knockout plus mechanistic pathway identification (PLD2→c-Src→occludin degradation)\",\n      \"pmids\": [\"28484281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PLD2 inhibitors FIPI and NFOT are mixed-kinetics inhibitors: FIPI acts at the S757 HKD2 catalytic site, whereas NFOT binds both the catalytic site (S757/S648) and an allosteric PIP2-binding pocket (R210/R212) in the PH domain.\",\n      \"method\": \"Enzyme kinetics analysis, site-directed mutagenesis, cancer cell invasion assay\",\n      \"journal\": \"Biochimica et Biophysica Acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — enzyme kinetics plus mutagenesis defining active and allosteric sites\",\n      \"pmids\": [\"25532944\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PLD2 interacts with and activates the Fes/Fps tyrosine kinase during myeloid differentiation; PLD2 co-immunoprecipitates with Fes, and PA and PIP2 stimulate Fes activity; PLD2 overexpression shortens the time required for granulocytic differentiation of HL-60 cells.\",\n      \"method\": \"Co-immunoprecipitation, Fes kinase activity assay with PA/PIP2, siRNA, overexpression, differentiation time-course analysis\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP plus in vitro kinase activation assay, single lab\",\n      \"pmids\": [\"22094461\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PLD2-generated PA directly binds IQGAP1 scaffold protein and promotes its plasma membrane recruitment; this PLD2-PA-IQGAP1 pathway is required for VSMC membrane ruffle formation and migration, and for injury-induced neointimal formation.\",\n      \"method\": \"PLD2 knockout mice (carotid ligation model), PA-IQGAP1 binding assay, IQGAP1 knockdown, PA-binding-deficient IQGAP1 mutant rescue, ruffle and migration assays\",\n      \"journal\": \"FASEB Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — in vitro binding assay plus mutagenesis plus in vivo knockout model\",\n      \"pmids\": [\"30811216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PLD1 couples to TLR4/MyD88 signaling for M1 macrophage polarization, while PLD2 couples to IL-4R/JAK3 signaling for M2 macrophage polarization; LPS enhances TLR4-PLD1 interaction and IL-4 induces IL-4R-PLD2 association.\",\n      \"method\": \"Co-immunoprecipitation, PLD isoform-specific knockouts (Pld1-LyzCre, Pld2-LyzCre), cytokine assays, in vivo sepsis and injury models\",\n      \"journal\": \"Journal of Cellular Physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific genetic knockouts plus co-IP and in vivo models\",\n      \"pmids\": [\"33368247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"S100B-RAGE interaction triggers activation of PLD2, which mediates ROS production and augments Ang II-induced JAK2 phosphorylation and VSMC proliferation.\",\n      \"method\": \"PLD2 inhibition, overexpression, RAGE-dependent signaling assays, ROS measurement, JAK2 phosphorylation assay\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — pharmacological inhibition and overexpression with functional signaling readout, single lab\",\n      \"pmids\": [\"12941779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Adipocyte-specific PLD2 deletion augments thermogenesis by improving mitochondrial quality and quantity via p62; PLD2 inhibition confers resistance to diet-induced obesity and insulin resistance.\",\n      \"method\": \"Adipocyte-specific Pld2 knockout mice, PLD2 pharmacological inhibition, mitochondrial quality assays, p62 pathway analysis\",\n      \"journal\": \"Journal of Experimental Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional knockout plus mechanistic pathway (PLD2→p62→mitochondria), single lab\",\n      \"pmids\": [\"34940790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PLD2 deletion protects against LPS-induced tight junction disruption in ALI via the PA/STAT3 axis; PLD2-generated PA increases STAT3 phosphorylation, which degrades endothelial tight junction proteins (claudin-5, occludin, ZO-1).\",\n      \"method\": \"PLD2 knockout mice, exogenous PA treatment, STAT3 inhibition, Western blot, permeability assays\",\n      \"journal\": \"International Immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout plus PA rescue plus STAT3 inhibitor, single lab\",\n      \"pmids\": [\"36700766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Mutation of PLD2-Y179F leads to increased AKT phosphorylation (T308 and S473) and DNA synthesis in a PI3K-dependent manner; activated Akt then phosphorylates PLD2 at T175 in a feedback loop; lipase activity (PA synthesis) is required for the DNA synthesis effect.\",\n      \"method\": \"Site-directed mutagenesis, PI3K inhibitor (LY294004), AKT phosphorylation assay, DNA synthesis (BrdU), ERK phosphorylation\",\n      \"journal\": \"Cellular Signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis plus pharmacological inhibition with mechanistic pathway defined, single lab\",\n      \"pmids\": [\"18006275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The C-terminal domain (residues 578–933) of PLD2 interacts with CKIIβ subunit and promotes its ubiquitin-dependent proteasomal degradation; PLD2 relocates CKIIβ to the plasma membrane, and this function is independent of PLD2 catalytic activity.\",\n      \"method\": \"Co-immunoprecipitation, deletion mutants, overexpression/knockdown, proteasome inhibitor, immunofluorescence\",\n      \"journal\": \"BMB Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — deletion mutagenesis plus co-IP plus functional degradation assay, single lab\",\n      \"pmids\": [\"21944249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PLD2 plays a role in retaining mutant KIT in the Golgi/TGN of GIST cells; KIT mut activates PLD2 through the PLCγ2–PKD2 cascade (independently of PI4KIIIβ), and PLD2 activity is required for γ-adaptin association with GGA1, mediating Golgi retention.\",\n      \"method\": \"PLD2 knockdown, PLD inhibitor (CAY10594), co-immunoprecipitation, immunofluorescence\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — knockdown plus pharmacological inhibition plus co-IP defining pathway position; preprint\",\n      \"pmids\": [\"bio_10.1101_2025.03.02.640696\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Oleate enhances PLD2 S-acylation at Cys223 and Cys224, disrupting PLD2 lipid raft localization and increasing its colocalization with PIP2-enriched microdomains; this modulation activates both PLD2 lipase activity and its GEF activity toward Cdc42. Mutation of S-acylation sites abolishes PLD2-mediated Cdc42 activation and filopodia formation.\",\n      \"method\": \"Confocal microscopy, lipid raft isolation, S-acylation assay, site-directed mutagenesis (Cys223/224), GEF activity assay, filopodia quantification\",\n      \"journal\": \"Journal of Lipid Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — S-acylation biochemistry plus mutagenesis plus GEF assay plus functional imaging\",\n      \"pmids\": [\"41223946\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PLD2 is a plasma membrane-associated phospholipase that hydrolyzes phosphatidylcholine to generate phosphatidic acid (PA), and additionally functions as a guanine nucleotide exchange factor (GEF) for Rac2 and Cdc42 via its PX/PH domains; its activity is regulated by direct binding to PIP2, EGF receptor (phosphorylation at Y11), Grb2 (via Y169/Y179 SH2 interaction), Cdk5 (phosphorylation at S134), JAK3 (Y415), PKCα, and oleate-induced S-acylation (Cys223/224), while PA produced by PLD2 acts as a second messenger that binds KIF5B and IQGAP1 to regulate vesicle trafficking and cell migration, activates mTORC1 via a direct PLD2-raptor complex, and controls membrane tension-linked actin nucleation through mTORC2, collectively placing PLD2 as a central lipid signaling node regulating exosome biogenesis, cell migration, chemotaxis, phagocytosis, tight junction integrity, and macrophage polarization.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PLD2 is a dual-function signaling enzyme that generates phosphatidic acid (PA) through phosphatidylcholine hydrolysis and independently acts as a guanine nucleotide exchange factor (GEF) for Rac2 and Cdc42 via its PX and PH domains, linking lipid signaling to cytoskeletal remodeling, vesicle trafficking, and cell migration [PMID:22106281, PMID:23035122, PMID:41223946]. PLD2 lipase activity is regulated by PIP2 generated through its physical interaction with Type Iα PIP kinase [PMID:11032811], and by phosphorylation events including EGF receptor-mediated Y11 phosphorylation [PMID:9837959], Cdk5-mediated S134 phosphorylation [PMID:18625302], JAK3-mediated Y415 phosphorylation [PMID:21414324], and Grb2 binding at Y169/Y179 [PMID:16407827], while oleate-induced S-acylation at Cys223/224 modulates both lipase and GEF activities by redistributing PLD2 from lipid rafts to PIP2-enriched membrane domains [PMID:41223946]. PA produced by PLD2 functions as a critical second messenger that activates mTORC1 through a direct PLD2–raptor complex [PMID:16837165], recruits KIF5B to vesicles for MT1-MMP surface delivery and cancer invasion [PMID:29033361], binds IQGAP1 to drive cell migration [PMID:30811216], and regulates tight junction integrity via c-Src-dependent occludin degradation [PMID:28484281]. PLD2 also serves as a plasma membrane tension sensor that controls actin nucleation through mTORC2 in neutrophil chemotaxis [PMID:27280401], mediates ARF6-dependent exosome biogenesis [PMID:24637612], and couples to IL-4R/JAK3 signaling to promote M2 macrophage polarization [PMID:33368247].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Establishing PLD2 as an EGF receptor-proximal signaling enzyme resolved how growth factor receptors directly regulate phospholipase D activity, revealing constitutive EGFR–PLD2 association and inhibitory Y11 phosphorylation as an activation switch.\",\n      \"evidence\": \"Co-IP, Y11F mutagenesis, and lipase activity assays in HEK293 cells\",\n      \"pmids\": [\"9837959\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Y11 phosphorylation regulates PLD2 in vivo\", \"Identity of the phosphatase that removes pY11\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrating that PLD2 activity in vivo depends on local PIP2 generated by a physically associated Type Iα PIP kinase resolved how PLD2 is regulated at steady state and defined a feed-forward lipid signaling module.\",\n      \"evidence\": \"Reciprocal co-IP and in vivo activity assays in COS7 cells\",\n      \"pmids\": [\"11032811\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the PLD2–PIPKIα interaction\", \"Whether other PIP kinase isoforms substitute\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identifying PKCα as a direct activator and physical interactor of PLD2 placed PLD2 downstream of calcium/DAG signaling, expanding the upstream inputs beyond receptor tyrosine kinases.\",\n      \"evidence\": \"Co-expression in Sf9 cells, IP, and membrane reconstitution assays\",\n      \"pmids\": [\"10838164\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"PKCα phosphorylation site on PLD2 not identified\", \"Single reconstitution system\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showing that alpha-synuclein inhibits PLD2 in vitro through its alpha-helical domain, with inhibition abolished by disease-relevant phosphorylations, linked PLD2 to potential Parkinson's disease-relevant lipid signaling.\",\n      \"evidence\": \"Reconstituted in vitro PLD2 activity assay with systematic alpha-synuclein mutants\",\n      \"pmids\": [\"15033366\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No in vivo or cellular validation of alpha-synuclein–PLD2 inhibition\", \"Physiological relevance in neurons unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identifying a direct PLD2–raptor complex mediated by a TOS-like motif and showing that both lipase activity and raptor binding are required for mTOR activation established PLD2 as a PA-dependent upstream activator of mTORC1.\",\n      \"evidence\": \"Co-IP, TOS motif mutagenesis, lipase-dead mutants, S6K1/4EBP1 phosphorylation in cells\",\n      \"pmids\": [\"16837165\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural detail of PA–mTOR interaction\", \"Relative contribution of PLD2 vs PLD1 to mTOR in different tissues\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrating that PLD2 lipase activity is essential for leukocyte chemotaxis and F-actin polarization answered whether PLD2 plays an effector role in immune cell migration.\",\n      \"evidence\": \"siRNA knockdown and lipase-dead mutant overexpression with chemotaxis and immunofluorescence in leukocytes\",\n      \"pmids\": [\"16873675\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GEF activity also contributes to chemotaxis at this point was unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Mapping two SH2 binding sites (Y169, Y179) for Grb2 on PLD2, with Y169 controlling lipase activity and Y179 controlling PLD2 phosphorylation state, defined how the adaptor Grb2 serves as a master regulator coupling PLD2 to both enzymatic activation and Ras/MAPK proliferative signaling.\",\n      \"evidence\": \"GST pull-down, co-IP, point mutants, ERK phosphorylation, and DNA synthesis assays\",\n      \"pmids\": [\"16407827\", \"17276458\", \"21419846\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether both Grb2 SH2 sites are engaged simultaneously or sequentially\", \"No structural model of PLD2–Grb2 complex\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identifying Cdk5-mediated S134 phosphorylation as necessary for EGF-dependent PLD2 activation placed PLD2 at an intersection of cell-cycle kinase and growth factor signaling, with functional consequence for insulin secretion.\",\n      \"evidence\": \"In vitro kinase assay, S134A mutagenesis, roscovitine inhibition, insulin secretion readout in beta cells\",\n      \"pmids\": [\"18625302\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether S134 phosphorylation modulates GEF activity\", \"In vivo relevance in pancreatic islets\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Discovering that PLD2 functions as a GEF for Rac2 through its PX/PH domains — independent of lipase activity — fundamentally revised PLD2's identity from a pure lipase to a bifunctional enzyme coordinating lipid signaling and Rho-family GTPase activation.\",\n      \"evidence\": \"Reconstituted in vitro GEF assay, FRET in living cells, Kd determination (~3 nM), systematic mutagenesis of CRIB motifs and PX domain\",\n      \"pmids\": [\"22106281\", \"21378159\", \"23035122\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure of PX domain bound to Rac2\", \"Whether PLD2 GEF activity is regulated by the same phosphorylations as lipase activity\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showing that JAK3 phosphorylates PLD2 at Y415 via a STAT-independent pathway to enable cancer cell invasion identified a new kinase input linking cytokine receptor signaling directly to PLD2-driven invasion.\",\n      \"evidence\": \"In vitro kinase assay, Y415 mutagenesis, siRNA, Matrigel invasion\",\n      \"pmids\": [\"21414324\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether JAK3–PLD2 axis operates in non-cancer cells\", \"No in vivo validation\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrating that ARF6 and PLD2 regulate syntenin-dependent exosome biogenesis by controlling ILV budding into MVBs revealed a lipid-driven mechanism for exosome production distinct from ESCRT-dependent pathways.\",\n      \"evidence\": \"siRNA, dominant-negative mutants, EM quantification, and functional rescue\",\n      \"pmids\": [\"24637612\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PA itself or a PA metabolite drives ILV budding\", \"Generalizability beyond syntenin cargo\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identifying PLD2 as a membrane tension sensor that limits actin nucleation through mTORC2 in neutrophils established a mechanotransduction pathway linking physical membrane properties to cell polarity and chemotaxis.\",\n      \"evidence\": \"Genetic knockout, optogenetic membrane tension manipulation, mathematical modeling, live-cell imaging\",\n      \"pmids\": [\"27280401\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How PLD2 senses tension mechanistically at the molecular level\", \"Whether mTORC2 is the sole effector\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showing that PLD2-generated PA directly binds KIF5B and is required for MT1-MMP vesicle trafficking, invadopodia formation, and metastasis identified a specific PA effector mediating PLD2's pro-invasive function.\",\n      \"evidence\": \"PLD2 knockout mice (MMTV-Neu), liposome pull-down, KIF5B mutagenesis, in vitro binding\",\n      \"pmids\": [\"29033361\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PA-binding site on KIF5B not structurally resolved\", \"Whether other kinesin family members also bind PA\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrating that PLD2 disrupts tight junctions via c-Src-mediated occludin phosphorylation and proteasomal degradation, with intestinal Pld2 knockout mice protected from colitis, established PLD2 as a pathogenic mediator of epithelial barrier breakdown.\",\n      \"evidence\": \"Conditional Pld2 knockout mice, DSS colitis model, Western blot, proteasome inhibitor rescue\",\n      \"pmids\": [\"28484281\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How PLD2 activates c-Src\", \"Whether PA or GEF activity mediates tight junction disruption\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identifying PA-dependent IQGAP1 plasma membrane recruitment as a PLD2 effector pathway in VSMC migration and neointimal formation provided a scaffold-mediated mechanism for PLD2's role in vascular remodeling.\",\n      \"evidence\": \"PLD2 knockout mice (carotid ligation), PA-IQGAP1 binding assay, PA-binding-deficient IQGAP1 mutant rescue\",\n      \"pmids\": [\"30811216\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of PA–IQGAP1 binding\", \"Whether PLD2–IQGAP1 axis operates in non-vascular contexts\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrating isoform-specific coupling of PLD2 to IL-4R/JAK3 for M2 macrophage polarization (versus PLD1/TLR4 for M1) resolved how two PLD isoforms play opposing immunomodulatory roles.\",\n      \"evidence\": \"Isoform-specific macrophage-targeted knockouts (Pld2-LyzCre), co-IP, cytokine assays, in vivo sepsis and injury models\",\n      \"pmids\": [\"33368247\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic basis of PLD2's selective coupling to IL-4R\", \"Whether PLD2 GEF activity contributes to M2 polarization\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Discovering that oleate-induced S-acylation at Cys223/224 redistributes PLD2 from lipid rafts to PIP2-enriched domains and activates both lipase and GEF (toward Cdc42) activities revealed a fatty acid–responsive post-translational switch coordinating PLD2's dual functions.\",\n      \"evidence\": \"S-acylation assay, Cys223/224 mutagenesis, lipid raft isolation, GEF activity assay, confocal microscopy\",\n      \"pmids\": [\"41223946\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the acyltransferase(s) responsible\", \"Whether other fatty acids similarly regulate PLD2 S-acylation\", \"In vivo metabolic relevance\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis of PLD2's bifunctional catalysis — how the same protein independently catalyzes phospholipid hydrolysis and GEF activity — remains unresolved, as no high-resolution structure of full-length PLD2 or its complexes with Rac2/Cdc42 is available.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal or cryo-EM structure of full-length PLD2\", \"How lipase and GEF activities are coordinated in real time during signaling\", \"Whether PLD2 tension sensing involves a conformational change or clustering mechanism\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [2, 3, 4, 5, 6, 14, 24]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [9, 16, 17, 34]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [2, 22, 24]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 8, 10, 22, 26, 34]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [0, 19, 21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 5, 11, 14, 15, 27, 31]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [0, 19, 21]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6, 20, 27]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [23, 30]}\n    ],\n    \"complexes\": [\n      \"PLD2–PIPKIα complex\",\n      \"PLD2–raptor–mTORC1 complex\",\n      \"PLD2–Grb2 complex\"\n    ],\n    \"partners\": [\n      \"GRB2\",\n      \"RAC2\",\n      \"EGFR\",\n      \"RPTOR\",\n      \"PIP5K1A\",\n      \"IQGAP1\",\n      \"KIF5B\",\n      \"JAK3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}